Compared with patients in the placebo group , patients in the active treatment groups ( standard and individualized CHM ) had significant improvement in bowel symptom scores as rated by patients ( P = .03 ) and by gastroenterologists ( P = .001 ) , and significant global improvement as rated by patients ( P = .007 ) and by gastroenterologists ( P = .002 ) .
